KalVista Pharmaceuticals, Inc. Banner Image

KalVista Pharmaceuticals, Inc.

  • Ticker KALV
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
KalVista Pharmaceuticals, Inc. Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can lead to increased vascular permeabilityMore, edema and inflammation. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista has created a structurally diverse portfolio of oral plasma kallikrein inhibitors and is advancing multiple drug candidates for HAE as well as DME.
KalVista Pharmaceuticals, Inc.

Most Recent Annual Report

KalVista Pharmaceuticals, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Older/Archived Annual Reports